Your SBIR Narrative Is Not a Pitch Deck

SBIR and STTR are running again. The programs lapsed at the end of September 2025, sat dormant for six months, and were reauthorized in April 2026 with authority through 2031 — along with a new category of larger "strategic breakthrough" Phase II awards, tighter foreign-risk diligence, and new limits on how many proposals a company can submit.

Agencies are issuing solicitations. University tech transfer offices are busy. And a particular kind of founder is starting to appear in angel screening meetings again: the spinout with real science, federal validation, and a pitch deck that isn't going to work.

Not because the company is weak. Because the deck is the wrong document.

---

Two Audiences That Reward Opposite Things

A grant reviewer is evaluating whether the science is sound, novel, and worth public money. The narrative that wins is dense with methodology, prior art, technical risk mitigation, and the credentials of the principal investigator. Commercial detail exists, but it lives in a section near the back and nobody's career depends on it.

An angel group is evaluating whether this becomes a company that returns capital. What wins there is evidence that someone will pay, a specific first market, a team that can sell as well as build, and a plausible path to an exit.

Both documents describe the same technology. Same facts, different burden of proof — different genres with different structures, different evidence standards, and different definitions of the word "risk."

To a grant reviewer, risk is technical: will this work?

To an investor, technical risk is one item on a list that also includes market risk, adoption risk, team risk, and timing — and by the time you're raising equity, they expect the technical question to be largely settled. That's what the federal money was for.

So when a spinout founder reformats a Phase II narrative into fifteen slides, the result is a deck that spends twelve slides answering a question the investor considers mostly resolved, and three slides on everything they actually care about.

---

What the Deck Should Do Instead

Lead with the customer, not the technology. The most common spinout deck opens with the science and arrives at the customer somewhere around slide nine. Invert it. The investor needs to know who has this problem, how badly, and what they currently do about it — before they can evaluate whether your solution matters. The technology is the reason you'll win, not the reason they should care.

Treat your grants as validation, not as a business model. This is the difference between a spinout that raises and one that doesn't. Angels like seeing grant money: federal funding absorbed your early technical risk, someone with subject-matter expertise reviewed your work and said yes, and your equity dollars now buy commercial progress instead of lab progress. Put that in the deck.

Don't make the grant pipeline your growth plan. A company whose next three milestones are all agency awards reads as a research organization, not a startup. Experienced angels have watched companies spend a decade on the grant treadmill producing excellent science and no enterprise value. They will pass, and they usually won't tell you that's why.

Translate technical milestones into commercial ones. Phase I proved feasibility. Phase II is building the thing. Neither is a milestone an investor can price. What they need on your Ask slide is what the equity buys: first paying pilot, regulatory submission filed, a manufacturing partner signed, a repeatable sales motion demonstrated. The strongest version connects both — here's the federal money doing the technical work, here's the equity doing the commercial work, and here's the milestone that makes the next round obvious.

Name a beachhead you could actually reach next year. Deep tech decks are unusually prone to the platform trap: the technology genuinely does apply to six industries, so the deck says so. To an investor, six markets means no market. Pick the one where the pain is sharpest, the sales cycle is shortest, and you already have a relationship — and let the other five live on a single "future applications" line.

Have an answer ready about your IP. Every angel group will ask who owns the technology, what the university license requires, what equity or royalty the institution holds, and what rights the government retained on federally funded work. A striking share of spinout founders arrive at their first round without clean answers. "The tech transfer office handles that" is not an answer — it's the end of the meeting. More on this in a follow-up post, because it deserves its own.

---

The Part That Feels Like a Downgrade

Founders coming out of a lab often experience this translation as dumbing down their work. Fifteen years of research compressed into one slide, while a customer interview count gets its own.

It isn't a downgrade. It's a different proof.

The grant proved the science. The deck has to prove the company. Those are separate claims, and each one needs its own evidence.

The founders who internalize that stop resenting the deck and start using it. They keep pursuing non-dilutive funding, because it's the cheapest capital they'll ever raise. They just stop confusing it with a fundraising strategy.

---

If You're Preparing Both This Fall

With solicitations flowing again and reauthorization secured through 2031, plenty of spinouts will be writing a grant proposal and an investor deck in the same quarter. A few practical notes:

Write them separately. The temptation to reuse language is enormous and it's where the contamination happens — grant phrasing in a deck is instantly recognizable to anyone who reads both.

Let each one borrow the right thing from the other. Your deck should borrow the grant's rigor about evidence; your grant should borrow the deck's clarity about who benefits.

And get the deck read by someone who evaluates companies rather than proposals, before the meeting that matters. The feedback is completely different, and the gap between the two is where spinouts lose rooms they should have won.

---

If you want to know how your deck reads to a screening committee rather than a review panel, upload it at VentureReady.ai. Slide-by-slide feedback against the investor framework — delivered in 24 hours.